March 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
The FDA has approved icotrokinra, an oral interleukin-23 receptor antagonist, for patients aged 12 years and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or...
Following the success of the reSURFACE clinical program, the US Food and Drug Administration has approved a new treatment option for adults with moderate to severe plaque psoriasis.
After clinical trials demonstrated its efficacy, the US Food and Drug Administration approved a biologic therapy for the treatment of patients with moderate to severe plaque psoriasis.
